Abstract
Although the pathophysiological mechanisms underlying the development of amyotrophic lateral sclerosis (ALS) remain to be fully elucidated, there have been significant advances in the understanding of ALS pathogenesis, with evidence emerging of a complex interaction between genetic factors and dysfunction of vital molecular pathways. Glutamate- mediated excitoxicity is an important pathophysiological pathway in ALS, and was identified as an important therapeutic biomarker leading to development of the only pharmacologically based disease-modifying treatment currently available for ALS. More recently, a putative role of voltage-gated persistent Na+ channels in ALS pathogenesis has been suggested and underscored by neuroprotective effects of Na+ channel blocking agents in animal models. In addition, advances in ALS genetics have lead to identification of novel pathophysiological processes that could potentially serve as therapeutic targets in ALS. Genetic therapies, including antisense oligonucleotide approaches have been shown to exert neuroprotective effects in animal models of ALS, and Phase I human trial have been completed demonstrating the feasibility of such a therapeutic approach. The present review summarises the advances in ALS pathogenesis, emphasising the importance of these processes as potential targets for drug development in ALS.
Keywords: Amyotrophic lateral sclerosis, clinical trial, excitotoxicity, glutamate, motor neuron disease, riluzole.
Current Medicinal Chemistry
Title:Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Volume: 21 Issue: 31
Author(s): Parvathi Menon, Matthew C. Kiernan and Steve Vucic
Affiliation:
Keywords: Amyotrophic lateral sclerosis, clinical trial, excitotoxicity, glutamate, motor neuron disease, riluzole.
Abstract: Although the pathophysiological mechanisms underlying the development of amyotrophic lateral sclerosis (ALS) remain to be fully elucidated, there have been significant advances in the understanding of ALS pathogenesis, with evidence emerging of a complex interaction between genetic factors and dysfunction of vital molecular pathways. Glutamate- mediated excitoxicity is an important pathophysiological pathway in ALS, and was identified as an important therapeutic biomarker leading to development of the only pharmacologically based disease-modifying treatment currently available for ALS. More recently, a putative role of voltage-gated persistent Na+ channels in ALS pathogenesis has been suggested and underscored by neuroprotective effects of Na+ channel blocking agents in animal models. In addition, advances in ALS genetics have lead to identification of novel pathophysiological processes that could potentially serve as therapeutic targets in ALS. Genetic therapies, including antisense oligonucleotide approaches have been shown to exert neuroprotective effects in animal models of ALS, and Phase I human trial have been completed demonstrating the feasibility of such a therapeutic approach. The present review summarises the advances in ALS pathogenesis, emphasising the importance of these processes as potential targets for drug development in ALS.
Export Options
About this article
Cite this article as:
Menon Parvathi, Kiernan C. Matthew and Vucic Steve, Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis, Current Medicinal Chemistry 2014; 21 (31) . https://dx.doi.org/10.2174/0929867321666140601161148
DOI https://dx.doi.org/10.2174/0929867321666140601161148 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commentary((Research Highlights)(Amyotrophic Lateral Sclerosis: Targeting the Body’s Energy Engine))
CNS & Neurological Disorders - Drug Targets Autophagy in Diabetic Retinopathy
Current Neuropharmacology Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease
Current Topics in Medicinal Chemistry Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Detrimental Effects of Apolipoprotein E4: Potential Therapeutic Targets in Alzheimers Disease
Current Alzheimer Research Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Inactivation of Parathyroid Hormone: Perspectives of Drug Discovery to Combating Hyperparathyroidism
Current Molecular Pharmacology Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
CNS & Neurological Disorders - Drug Targets An Overview of Drug Screening Using Primary and Embryonic Stem Cells
Combinatorial Chemistry & High Throughput Screening Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases
Current Pharmaceutical Design The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics Inhibitors of Cyclin-Dependent Kinases: Potential Drugs for the Treatment of Neurodegenerative Disorders?
Current Medicinal Chemistry - Central Nervous System Agents